雷珠单抗与贝伐珠单抗治疗新生血管性年龄相关性黄斑变性:两年结果
这项多中心随机临床试验纳入1185例新生血管性年龄相关性黄斑变性患者,第二年随访1107例,比较雷珠单抗与贝伐珠单抗按月或按需给药的效果。两年内两药视力获益相似,按月给药视力增益大于按需给药,贝伐珠单抗系统性严重不良事件比例更高。
要点
- 两药两年视力增益相似,贝伐珠单抗与雷珠单抗差值为-1.4个字母。
- 按月给药视力增益大于按需给药,差值为-2.4个字母。
- 贝伐珠单抗系统性严重不良事件比例高于雷珠单抗(39.9% vs 31.7%)。
核心结论
- 雷珠单抗与贝伐珠单抗两年内对视力影响相似。
- 按需治疗视力增益较少,无论入组时即按需或按月治疗一年后转按需。
- 两药死亡和动脉血栓事件率无差异,贝伐珠单抗系统性严重不良事件比例更高但解释不确定。
研究设计与样本
- 多中心随机临床试验,纳入1185例新生血管性年龄相关性黄斑变性患者,第二年随访1107例。
- 入组时按药物和给药方案分为四组,治疗一年后按月组随机再分为按月或按需,不改变药物分配。
主要发现
- 两年同方案治疗者两药视力增益相似,贝伐珠单抗与雷珠单抗差值为-1.4个字母(95%CI -3.7至0.8,P=0.21)。
- 按月给药视力增益大于按需给药,差值为-2.4个字母(95%CI -4.8至-0.1,P=0.046)。
- 无液体比例从贝伐珠单抗按需组的13.9%到雷珠单抗按月组的45.5%(药物P=0.0003,方案P<0.0001)。
- 按月转按需治疗导致第二年视力平均下降更多(-2.2个字母,P=0.03),无液体比例降低19%(P<0.0001)。
- 贝伐珠单抗系统性严重不良事件比例高于雷珠单抗(39.9% vs 31.7%;调整风险比1.30;95%CI 1.07-1.57;P=0.009)。
关键数值与推荐
- 两药两年视力增益差值-1.4个字母(95%CI -3.7至0.8,P=0.21)。
- 按月与按需视力增益差值-2.4个字母(95%CI -4.8至-0.1,P=0.046)。
- 无液体比例范围13.9%至45.5%(药物P=0.0003,方案P<0.0001)。
- 按月转按需第二年视力下降-2.2个字母(P=0.03),无液体比例降低19%(P<0.0001)。
- 贝伐珠单抗与雷珠单抗系统性严重不良事件39.9% vs 31.7%(调整风险比1.30;95%CI 1.07-1.57;P=0.009)。
临床怎么用
- 可考虑雷珠单抗或贝伐珠单抗治疗新生血管性年龄相关性黄斑变性,两药两年视力效果相似。
- 按月给药视力增益优于按需给药,临床决策需权衡治疗负担与视力获益。
- 贝伐珠单抗系统性严重不良事件比例较高,需关注但解释不确定。
局限性
- 贝伐珠单抗较高严重不良事件率的解释不确定,因缺乏与VEGF抑制相关条件的特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment. DESIGN: Multicenter, randomized clinical trial. PARTICIPANTS: Patients (n = 1107) who were followed up during year 2 among 1185 patients with neovascular age-related macular degeneration who were enrolled in the clinical trial. INTERVENTIONS: At enrollment, patients were assigned to 4 treatment groups defined by drug (ranibizumab or bevacizumab) and dosing regimen (monthly or as needed). At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the drug assignment. MAIN OUTCOME MEASURES: Mean change in visual acuity. RESULTS: Among patients following the same regimen for 2 years, mean gain in visual acuity was similar for both drugs (bevacizumab-ranibizumab difference, -1.4 letters; 95% confidence interval [CI], -3.7 to 0.8; P = 0.21). Mean gain was greater for monthly than for as-needed treatment (difference, -2.4 letters; 95% CI, -4.8 to -0.1; P = 0.046). The proportion without fluid ranged from 13.9% in the bevacizumab-as-needed group to 45.5% in the ranibizumab monthly group (drug, P = 0.0003; regimen, P < 0.0001). Switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2 (-2.2 letters; P = 0.03) and a lower proportion without fluid (-19%; P < 0.0001). Rates of death and arteriothrombotic events were similar for both drugs (P > 0.60). The proportion of patients with 1 or more systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9% vs. 31.7%; adjusted risk ratio, 1.30; 95% CI, 1.07-1.57; P = 0.009). Most of the excess events have not been associated previously with systemic therapy targeting vascular endothelial growth factor (VEGF). CONCLUSIONS: Ranibizumab and bevacizumab had similar effects on visual acuity over a 2-year period. Treatment as needed resulted in less gain in visual acuity, whether instituted at enrollment or after 1 year of monthly treatment. There were no differences between drugs in rates of death or arteriothrombotic events. The interpretation of the persistence of higher rates of serious adverse events with bevacizumab is uncertain because of the lack of specificity to conditions associated with inhibition of VEGF. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. Ophthalmology. 2020. PMID: 32200813. doi:10.1016/j.ophtha.2020.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。